# Summary of Clinical Trial Results

## A study to look at how safe different doses of a new medicine (GDC-5780) were

See the end of the summary for the full title of the study.

## About this summary

This is a summary of the results of a clinical trial (called a "study" in this document) to look at how safe a medicine was when taken by healthy people.

This summary is written for:

- Members of the public
- People who took part in the study

The study started in February 2022 and finished in October 2022. This summary was written after the study had ended. This summary is based on information known at the time of writing.

No single study can tell us everything about the risks and benefits of a medicine. It takes many people in several studies to find out everything we need to know. The results from this study may be different from other studies with the same medicine.

- **This means that you should not make decisions based on this one study**
- **Always speak to your doctor before making any decisions about your treatment**

### Contents of this summary



### Thank you to the people who took part in this study

The people who took part in this study have helped researchers answer important questions about the new medicine, GDC-5780.

## Key information about this study

- This study was done to find out if a new medicine, called "GDC-5780," was safe to give to people.
- GDC-5780 was given slowly through a vein (intravenous (IV) infusion).
- Researchers looked at the number and types of side effects caused by GDC-5780 at different doses.
- This study included 56 healthy people in one country, the USA.
- The main finding was that most people could tolerate GDC-5780. However, several people got side effects that were thought to be caused by the study medicine. There were no serious side effects in this study.
- GDC-5780 was tolerated better when the infusion time was adjusted, or if people took a medicine for allergic reactions (antihistamines) before the GDC-5780 treatment.

# 1. General information about this study

## Why was this study done?

Many people suffer from urinary tract infections (**UTI**). These are infections of the human body part through which urine passes. UTI are some of the most common infections caused by bacteria in people.

In certain situations, a UTI is called a "complicated UTI." This happens in people with a different (abnormal) urinary tract or in people who use a tube (catheter) to empty the bladder.

Antibiotics are medicines used for treating bacterial infections. Complicated UTI can be caused by bacteria that are not killed by most antibiotics (multidrug-resistant bacteria).

Complicated UTI can lead to needing to be treated in a hospital and can also cause death.

A class of antibiotics called "carbapenems" is used for treating complicated UTI caused by multidrug-resistant bacteria. Because these antibiotics have been used a lot, it has led to the creation of bacteria that can no longer be killed by carbapenems (carbapenem-resistant bacteria).

There is a need for developing new antibiotics for infections caused by multidrug-resistant bacteria.

The study medicine, GDC-5780, is a new antibiotic. It has been designed to treat people with complicated UTI caused by a type of multidrug-resistant bacteria, including carbapenem-resistant bacteria.

Multidrug-resistant bacteria are not resistant to GDC-5780 because it is a new type of antibiotic.

This study was done to find out if GDC-5780 was safe to give to people. Researchers wanted to know what the side effects were at different doses, and if the side effects could be tolerated by people.

## What was the study medicine?

People in this study got a study medicine called "**GDC-5780,**" an antibiotic that has been designed to kill multidrug-resistant bacteria. This medicine may be useful for people who have complicated UTI.

Some people in this study got a "**placebo**." The placebo looked like the real medicine, but it did not contain any real medicine.

People got their treatments through an IV infusion.

## What did researchers want to find out?

Researchers did this study to compare GDC-5780 with the placebo. If the people in the study had side effects, they wanted to understand which side effects were caused by GDC-5780 and which side effects were due to the placebo.

**The main question that researchers wanted to answer was:**

1. Was it safe to give GDC-5780 to people?

## What kind of study was this?

Here are some features of this study.

**Phase 1 study**
This was a "Phase 1" study, which means that this was a study with a small number of healthy people getting the medicine. Researchers asked questions and did medical tests to find out more about the effects on people.

**Randomized study**
A computer randomly decided who got GDC-5780 and who got placebo. Researchers and people had no control over this.

**Double-blind study**
This was a "double-blind" study, which means that neither the people enrolled in the study nor the researchers conducting the study knew who was getting GDC-5780 and who was getting the placebo.

**Single Ascending Dose (SAD) study**
This was a "single ascending dose" (SAD) study, which means each group received a single treatment of GDC-5780 or placebo, and the dose was increased for each new group.

The first group got the lowest dose of GDC-5780. It was planned that each new group of people would receive the next higher dose.

The decision to increase the dose level for the next group was made after reviewing safety results from people who had already been treated at the lower dose levels.

**Placebo-controlled study**
Some people got GDC-5780 while others got a placebo. This was done so that the treatment with GDC-5780 could be compared to the treatment with placebo – to find out the real effect of GDC-5780.

### When and where did the study take place?

The study started in February 2022 and finished in October 2022. This summary was written after the study had ended.

The study took place at one study center in one country – the USA.

## 2. Who took part in this study?

Fifty-six healthy people took part in this study.




**People could take part in the study if they met all of the following conditions:**

- Understood and signed the informed consent form
- Between 18 to 65 years old
- Met the height to weight ratio (BMI 18.5 to 30 kg/m$^2$)
- In good health – the doctors asked questions, did medical exams, and blood tests
- No blood donation during study
- No eating or drinking items from a list of restricted items – some restrictions were for the duration of the entire study and others were for a shorter duration
- No drugs or alcohol for a required time
- No strenuous exercise for a required time
- Agreement to use birth control for a required time

**People could not take part in the study if they met any one of the following conditions:**

- Women who were pregnant, breast feeding, or intended to become pregnant during the study or shortly thereafter
- Had a surgery planned during the study
- Did not meet a list of health requirements – the doctors asked questions, did medical exams, and blood tests
- Did not meet the mental health requirements
- Recent history or current use of controlled substances
- Current use of more than the allowed amount of alcohol
- Recently participated in another study with another study medicine
- Recent history or current use of prescription medicines or over-the-counter non-prescription items that were not allowed
- Recent history or current use of tobacco or nicotine products
- Recent history of donating blood

## 3. What was done during the study?

### Screening Period

People showed up at the clinic up to 28 days before the treatment started – to find out if they met all the conditions for joining the study.

### Treatment Period

People checked into the clinic two days before treatment. They went home three days after the treatment.

There were seven different dose groups. Eight people joined each group.

People were selected – at random by a computer – to get one of two treatments: GDC-5780 or the placebo.

Six people got GDC-5780 and two got a placebo in each dose group.

People got treatments through an IV infusion. Treatments were given to one group at a time.

People provided blood and urine samples at different times. They answered questions and reported any side effects that they experienced.

Researchers looked at the side effects in a group – before they decided if it was safe to increase the dose for the next group.

Researchers decided to test different infusion times in later groups. They also looked at the effect of giving medicines for allergic reactions – **antihistamines** – to people in the study before an IV infusion.

### End of Study

People went back to the clinic on certain days for follow-up visits. They answered questions, provided blood and urine samples, and reported any side effects.

## 4. What were the results of the study?

### **Study Question 1:** Was it safe to give GDC-5780 to people?

Researchers looked at the treatment-related side effects, how severe were they, and how many people had them.

- There were no serious side effects and no deaths due to side effects in this study.
- Some people had side effects caused by the study treatment that were not serious.
- Side effects are explained in greater detail in Section 5.

Based on the results in this study, researchers decided a single dose of GDC-5780, given by IV infusion, was safe when given to healthy people.

- The side effects could be tolerated by people and managed (treated) by doctors.
- The side effects did not cause long-term damage.

Researchers found that GDC-5780 was better tolerated when:

- The infusion time was adjusted.
- People took a medicine for allergic reactions (antihistamines) before GDC-5780 dosing.

This section only shows the key results from this study. You can find other information about this study on the websites listed at the end of this summary (see Section 8).

## 5. What were the side effects?

Side effects are medical problems (such as feeling dizzy) that happened during the study.

- They are described in this summary because the study doctor believes the side effects were related to the treatments in the study.
- Not all of the people in this study had all of the side effects.
- Side effects may be mild to very serious and can be different from person to person.
- It is important to be aware that the side effects reported here are from this single study. Therefore, the side effects shown here may be different from those seen in other studies, or those that appear on the medicine leaflet.
- Serious and common side effects are listed in the following sections, if they were seen in this study.

### Serious side effects

A side effect is considered “serious” if it is life-threatening, needs hospital care, or causes lasting problems.

- No one in this study experienced a serious side effect.
- No one in this study died due to side effects.

### Most common side effects

Twenty-one people (38%) out of 56 in this study had side effects – that were not serious – but study doctors thought they were caused by the study treatment (either GDC-5780 or placebo):

- Eighteen people (43%) out of 42 who received GDC-5780
- Three people (21%) out of 14 who received placebo

The most common side effects are listed in the table below. Each was seen in 2 or more people in the study. Some people had more than one side effect. All side effects stopped (resolved) by the time the study ended.

| Side effect | Number of people who got side effect with GDC-5780 | Number of people who got side effect with placebo |
|---|---|---|
| Itching of the skin (pruritus) | 12 (29%) | 0 |
| Headache | 5 (12%) | 1 (7%) |
| A sensation of blood rushing to the head (orthostatic) | 4 (10%) | 0 |
| A tingling "pins and needles" feeling in the limbs (paresthesia) | 3 (7%) | 1 (7%) |
| Feeling warm and turning red in the face (flushing) | 2 (5%) | 0 |
| Stomach discomfort due to indigestion and feeling full (dyspepsia) | 2 (5%) | 0 |
| Feeling sick to stomach (nausea) | 2 (5%) | 0 |
| Feeling hot | 2 (5%) | 0 |
| Feeling dizzy | 2 (5%) | 0 |

Because of side effects, the IV infusion was briefly paused and then restarted – for four people (10%) who received GDC-5780. That means, the IV infusion took longer than planned.

Because of side effects, the IV infusion was stopped for one person.

- One person in the highest dose group received only part of the dose of GDC-5780 that was intended to be given
- The side effect was an allergic reaction that caused swelling and fluid build-up under the skin – "angioedema"
- While the treatment was stopped, the person stayed in the study and completed all follow-up visits
- The side effect went away (resolved) by the time the study ended

### Other information

You can find other information (not shown in the sections above) on the websites listed at the end of this summary – see Section 8.

## 6. How has this study helped research?

The information presented here is from a single study of 56 healthy people. This was the first time GDC-5780 was given to people.

Researchers found all doses of GDC-5780 that were tested – to be safe to give to healthy people. While side effects were seen, they could be managed by doctors and tolerated by people. All side effects stopped (resolved) by the time the study ended.

No single study can tell us everything about the risks and benefits of a medicine. It takes many people in several studies to find out everything we need to know. The results from this study may be different from other studies with the same medicine.

- **This means that you should not make decisions based on this one study summary**
- **Always speak to your doctor before making any decisions about your treatment**

## 7. Are there plans for other studies?

Further studies with GDC-5780 are planned.

## 8. Where can I find more information?

You can find more information about this study on the websites listed below:

- https://www.isrctn.com/ISRCTN16073754
- https://forpatients.roche.com/en/trials/healthy-volunteers/a-phase-i--randomized--double-blind-single-ascending-dose-studyt.html

### Who can I contact if I have questions about this study?

If you have any further questions after reading this summary:

- Visit the ForPatients platform and fill out the contact form at https://forpatients.roche.com/en/About.html
- Contact a representative at your local Roche office

If you took part in this study and have any questions about the results:

- Speak with the study doctor or staff at the study hospital or clinic

If you have questions about your own treatment:

- Speak to the doctor in charge of your treatment

### Who organized and paid for this study?

This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under Other Transactional Agreement number: HHSO100201800036C. The findings and conclusions herein are those of the authors and do not necessarily represent the views of the Department of Health and Human Services or its components.

This study was organized and also paid for by Genentech, Inc., South San Francisco, CA, USA. Genentech is part of F. Hoffmann-La Roche Ltd., with headquarters in Basel, Switzerland.

## Full title of the study and other identifying information

The full title of this study is:

> A phase 1, randomized, double-blind, single ascending dose study to evaluate the safety and pharmacokinetics of GDC-5780 in healthy subjects

- The protocol number for this study is GV43221
- The International Standard Randomized Controlled Trial Number (ISRCTN) identifier for this study is 16073754